thalidomide has been researched along with Hemophilia A in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hemophilia A: The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide was discontinued after 10 days due to exacerbation of renal dysfunction." | 5.42 | Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide. ( Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y, 2015) |
| "Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII." | 2.66 | Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature. ( Andres, M; Angelillo-Scherrer, A; Dickenmann, M; Jalowiec, KA; Kremer Hovinga, JA; Musa, A; Rovó, A; Taleghani, BM, 2020) |
| "Lenalidomide was discontinued after 10 days due to exacerbation of renal dysfunction." | 1.42 | Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide. ( Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jalowiec, KA | 1 |
| Andres, M | 1 |
| Taleghani, BM | 1 |
| Musa, A | 1 |
| Dickenmann, M | 1 |
| Angelillo-Scherrer, A | 1 |
| Rovó, A | 1 |
| Kremer Hovinga, JA | 1 |
| Saburi, M | 1 |
| Ohtsuka, E | 1 |
| Itani, K | 1 |
| Nagamatsu, K | 1 |
| Ikebe, T | 1 |
| Miyazaki, Y | 1 |
| Ogata, M | 1 |
| Saburi, Y | 1 |
1 review available for thalidomide and Hemophilia A
| Article | Year |
|---|---|
Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature.
Topics: Aged; Factor VIII; Hemophilia A; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Thalido | 2020 |
1 other study available for thalidomide and Hemophilia A
| Article | Year |
|---|---|
Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hemophilia A; Hum | 2015 |